Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated
peripheral blood mononuclear cells following bone marrow transplantation
E Katsanis, PM Anderson, AH Filipovich, DE Hasz, ML Rich, CM Loeffler, AC Ochoa and DJ Weisdorf
Department of Pediatrics, University of Minnesota, Minneapolis 55455.
We evaluated the proliferation, cytolytic function, and phenotypic
characteristics of anti-CD3 plus interleukin-2 (IL-2) stimulated peripheral
blood mononuclear cells (PBMCs) from 44 patients with leukemia or
non-Hodgkin's lymphoma (NHL) treated with multiagent chemotherapy or
following bone marrow transplantation (BMT). BMT patients had decreased
cell growth with only a 1.35 +/- 0.25 (autologous BMT for acute
lymphoblastic leukemia [ALL]), 1.24 +/- 0.25 (autologous BMT for NHL), and
0.8 +/- 0.1 (allogeneic BMT for leukemia) mean fold increase by day 5 of
culture compared with controls (4.0 +/- 0.4), P less than .001. Anti-CD3 +
IL-2 activated cells from patients with ALL and NHL who had received
autologous BMT and cells from patients with leukemia who underwent
allogeneic BMT were more effective in lysing the natural killer (NK)
sensitive target, K562, and the NK- resistant target, Daudi, compared with
controls. In contrast, cytolysis of K562 and Daudi by cultured PBMCs from
patients with ALL and NHL receiving multi-agent chemotherapy was similar to
that of controls. Cultures from BMT recipients had a significant increase
in CD16+ (autologous ALL 5.7 +/- 1.5%, P less than .01; autologous NHL 12.4
+/- 3.5%, P less than .001; allogeneic 14.3 +/- 2.9%, P less than .001) and
CD56+ cells (autologous ALL 27.6 +/- 12.0%, P less than .01; autologous NHL
39.3 +/- 9.5%, P less than .001; allogeneic 42.7 +/- 7.4%, P less than
.001) compared with controls (CD16+ 2.5 +/- 0.4%; CD56+ 6.9 +/- 0.9%).
Stimulation of PBMCs with anti-CD3 + IL-2 is effective in generating cells
with high cytolytic function post-BMT.
Volume 78,
Issue 5,
pp. 1286-1291,
09/01/1991
Copyright © 1991 by The American Society of Hematology
